The Goldman Sachs Group Inc. 'AA-/A-1+' Ratings Affirmed; Outlook Negative Jun 08

  • ID: 1783506
  • June 2008
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) June 2, 2008--Standard & Poor's Ratings Services said today that it affirmed its 'AA-/A-1+' counterparty credit ratings on The Goldman Sachs Group Inc. (GS [holding company]), as part of our global securities industry review. (See "S&P Completes Review Of Global Securities Industry; Ratings Lowered On Morgan Stanley, Merrill Lynch & Co. Inc., And Lehman Brothers Holdings Inc.; Outlooks Negative," published June 2, 2008, on RatingsDirect.) The outlook is negative. Among major players in the securities industry, GS has one of the heaviest concentrations in trading and investment banking. Although it is one of the largest asset managers, it lacks a presence in the retail brokerage business or other business lines. Within trading, GS puts particular...

Companies mentioned in this report are:
- The Goldman Sachs Group Inc.

Action: Affirmed
Action: Outlook: Negative

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- The Goldman Sachs Group Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.